Mfg Part Number
Ab04184-10.0
Vector Labs Ab04184-10.0 Anti-FAP alpha [BIBH1 (Sibrotuzumab, huF19)], Human IgG1, kappa (100 μg)
Quick Overview
The parental mouse antibody F19 was generated by immunizing mice with lung fibroblasts. The original humanized version of the antibody was generated by grafting of CDRs from the parental mouse antibody onto human framework regions.
$570.70
Order will ship within 1-3 business days
| Product Class: | Purified |
|---|---|
| Clone ID: | BIBH1 (Sibrotuzumab, huF19) |
| Synonyms: | Seprase; Fibroblast activation protein; Prolyl endopeptidase FAP; 170 kDa melanoma membrane-bound gelatinase; Dipeptidyl peptidase FAP; FAPalpha; Fibroblast activation protein alpha; Gelatin degradation protease FAP; Integral membrane serine protease; Post-proline cleaving enzyme; Serine integral membrane protease; SIMP; Surface-expressed protease |
| Amount: | 100 μg |
| Application Codes Clone: | FC; IHC; ELISA |
| Shipping Temperature: | Wet Ice |
| Buffer Composition: | PBS with 0.02% Proclin 300. |
| Original Format: | IgG1 |
| Storage Temperature: | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C. |
| Specificity Statement: | This antibody binds specifically to human fibroblast activation protein (FAP). This protein is a cell surface glycoprotein serine protease that participates in extracellular matrix degradation and is involved in many cellular processes including tissue remodeling, fibrosis, wound healing, inflammation and tumor growth. This antibody does not cross react with rat, mouse, rabbit or cynomolgus monkey FAP. |
| Application Notes: | The binding characterization of this antibody towards surface expressed FAP was done using flow cytometry. An in vitro assay with either human complement or with human MNC as effector mechanisms revealed no detectable cytotoxic effects on FAP-expressing tumor cell line HT-1080FAP clone33. This antibody was also used in the immunohistochemical analysis of normal and neoplastic human tissues. This antibody was also capable of binding recombinant human FAP in an ELISA (WO1999057151). A phase I biodistribution studywith 131I-labelled mAb F19 was carried out in 17 presurgical patients with hepatic metastases from colorectal cancer (PMID: 8201382). Another study investigated the anti-tumor activity, safety and pharmacokinetics of this antibody in patients with metastatic colorectal cancer. It concluded that this antibody was well tolerated and safe (PMID: 12624517). In another dose escalation study of sibrotuzumab, in patients with advanced FAP-positive cancer, it was concluded that this antibody can be safely administered to patients (PMID: 12738716). Phase 1 and 2 clinical trials of sibrotuzumab did not accomplish a good outcome. The block of the enzymatic activity of FAP with small molecule inhibitors also resulted in lower survival rates for the patients (PMID: 30781344). |
| Brand | Vector Labs |
|---|---|
| UNSPSC | 12161500 |